Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06039449 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2
A Phase 3 study, sponsored by Invivyd.
- Completed
- Registry status
- Phase 3
- Development phase
- 790
- Enrollment target
NCT06039449 is a Phase 3 study that has completed, run by Invivyd. The registered enrollment target is 790 participants.
The verdict
NCT06039449, a Phase 3 study, has completed, sponsored by Invivyd.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 790 participants
- Enrollment target
Study Summary
A study to investigate the prevention of COVID-19 with VYD222 in adults with immune compromise and in participants aged 12 years or older who are at risk of exposure to SARS-CoV-2
Interventions
- DRUG Normal saline
- DRUG VYD222 (pemivibart)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 790 participants |
| Start Date | 2023-09-08 |
| Est. Completion | 2024-11-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06039449
The ClinicalTrials.gov registry entry for NCT06039449 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 790 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Invivyd, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normal saline is the first listed.
NCT06039449 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06039449 about?
NCT06039449 is a clinical study titled "A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2". A study to investigate the prevention of COVID-19 with VYD222 in adults with immune compromise and in participants aged 12 years or older who are at risk of exposure to SARS-CoV-2
What is the current status of trial NCT06039449?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 790 participants. The study started on 2023-09-08. Estimated completion is 2024-11-19.
What interventions are being tested in trial NCT06039449?
The interventions under investigation include: Normal saline (DRUG), VYD222 (pemivibart) (DRUG).
Who is sponsoring clinical trial NCT06039449?
This trial is sponsored by Invivyd, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.